Amgen has made a play in a hot area of immunology R&D, paying $400 million upfront to claim rights to an OX40-targeting drug from Kyowa Kirin that is ready for phase 3 testing for atopic ...

KY1005 works by bonding to the OX40-Ligand (OX40-L), which forms an important part of the process that activates the immune system. Interaction between OX40-L and its binding partner OX40 have ...